PATIENTS with autoimmune hepatitis (AIH) and decompensated cirrhosis achieved hepatic recompensation following immunosuppressive therapy, according to a study that also identified clinical and inflammatory factors linked to recovery.
AIH is a chronic immune-mediated liver disease characterised by ongoing hepatic inflammation and marked clinical heterogeneity, with presentations ranging from asymptomatic disease to acute liver failure and advanced cirrhosis.
Decompensated cirrhosis develops when complications such as ascites, variceal bleeding or hepatic encephalopathy emerge, reflecting declining hepatic reserve and poorer prognosis.
Baseline Liver Function and Nutritional Status Linked to AIH Recompensation
The single-centre retrospective cohort study included 81 patients with biopsy-confirmed AIH and decompensated cirrhosis treated at West China Hospital of Sichuan University between January 2011 and August 2024.
All patients received immunosuppressive therapy, with 34.6% achieving hepatic recompensation according to Baveno VII criteria. Median time to recompensation was 32.1 months.
The patients who achieved recompensation had significantly higher baseline BMI, albumin and alanine aminotransferase (ALT) levels than those who remained decompensated. Diabetes was less common in the recompensated group.
Patterns of decompensation also differed between groups. Mild ascites was more frequently observed among recompensated patients, whereas large-volume ascites and bleeding complications were more common in persistently decompensated patients.
Multivariate analysis identified higher BMI, albumin, ALT and complete biochemical remission at six months as independent predictors of recompensation, while diabetes reduced the likelihood of recovery.
The investigators suggested that higher ALT levels may indicate ongoing but treatment-responsive inflammation, potentially reflecting a therapeutic window for immunosuppressive intervention. Higher albumin levels may indicate preserved synthetic liver function and regenerative capacity.
Lower Inflammatory Cytokines Tied to Hepatic Recovery
Patients who achieved recompensation also demonstrated lower baseline levels of inflammatory cytokines including IL-17A, TNF-α, and IFN-γ, suggesting that a less pronounced inflammatory environment may support hepatic recovery.
Liver function improved substantially in recompensated patients. More than 80% improved from Child–Pugh class B to class A, while the remainder improved from class C to class A.
The authors acknowledged several limitations, including the single-centre design, the predominance of ascites-related decompensation and the lack of repeat liver biopsies to confirm histological improvement. They also noted that recompensation is a dynamic state requiring lifelong disease-directed treatment, regular monitoring and proactive infection management.
Overall, the findings highlight the importance of early risk stratification in AIH-related decompensated cirrhosis. Baseline nutritional status, preserved liver synthetic function and metabolic comorbidities such as diabetes may help clinicians identify patients with greater potential for hepatic recovery during immunosuppressive treatment.
Reference
Zhang Y et al. Predictors of recompensation in immunosuppressive therapy for biopsy-proven autoimmune hepatitis patients with decompensated cirrhosis. Ann Hepatol. 2026;DOI:10.1016/j.aohep.2026.102221.
Featured image: Nadzeya on Adobe Stock
